Peptide therapy claims on TikTok: hype vs. human data

What did @drchriscalapai actually say?

The creator describes a patient two months into somorelin therapy who reportedly feels "20 years younger," crediting improvements in sleep, memory, hair growth, libido, and workout performance. He frames somorelin as "a precursor to IGF-1, just like growth hormone," and closes with a line that stuck out: "all we did was bring you to where you were before." That last part is doing a lot of work, and it matters whether it's true.

To be clear about what somorelin is: it's a synthetic form of growth hormone-releasing hormone (GHRH), meaning it signals the pituitary to produce more growth hormone, which then stimulates IGF-1 production in the liver. The pathway is real. The anecdote, though, is a single patient report with no baseline labs quoted, no control, and outcomes that conveniently match every benefit the creator listed upfront.

Does the science back this up?

Partially, but the evidence base is thinner than this video implies, and the benefit list is inflated. The GHRH-GH-IGF-1 axis is well-documented, and declining GH secretion with age is a real phenomenon. What's less established is that boosting that axis in otherwise healthy adults produces the dramatic multi-system improvements described here.

A 2019 review by Sigalos and Pastuszak in Sexual Medicine Reviews found modest evidence for GHRH analogues improving body composition and sleep architecture, particularly slow-wave sleep, which aligns with the patient's sleep claim. However, the same review noted that quality-of-life outcomes in non-deficient adults are inconsistent across trials. On memory and cognition, a notable study by Bherer et al. (2010, Neurobiology of Aging) examined sermorelin-adjacent GHRH peptides in older adults and found some improvements in cognitive processing speed, but the effects were modest and population-specific. Lumping in hair growth and libido as IGF-1 benefits without citing evidence is a stretch the data doesn't support cleanly.

What did they get wrong (or right)?

The mechanism description is mostly accurate. GHRH analogues like somorelin do stimulate GH release, and GH does drive hepatic IGF-1 production. Calling somorelin "a precursor to IGF-1" is a simplification, but not wrong in the causal chain sense.

What is problematic is the benefit list. Presenting hair, skin, nails, fat burning, muscle strength, mood, memory, and libido as an IGF-1 package deal, as if each has equal evidentiary weight, is misleading. Some have more support than others. Fat distribution and lean mass changes have reasonable backing in GH-deficient populations (Molitch et al., 2011, Journal of Clinical Endocrinology and Metabolism). Hair growth as a direct IGF-1 benefit in adults without documented deficiency is speculative.

The framing of "bringing her back to where she was before" also implies measurable deficiency was documented and corrected. If labs were run and showed low IGF-1, that's clinically defensible. The video doesn't say that. An anecdote without baseline data isn't evidence, and presenting it as validation of a treatment protocol sets a low bar for a regulated practice.

What should you actually know?

Somorelin and other GHRH analogues are compounded peptides. They are not FDA-approved for anti-aging or optimization use in healthy adults. Their legal prescribing context in the U.S. involves documented GH deficiency, not the general goal of "functioning like you did 20 years ago."

The IGF-1 axis is genuinely important, and there is legitimate clinical interest in GHRH peptides for appropriate patients. But IGF-1 is also a growth factor, and elevated IGF-1 has been associated with increased cancer risk in some epidemiological studies, including work by Pollak (2012, Nature Reviews Cancer). That tradeoff never comes up in this video, and it should.

If a provider is recommending any peptide therapy to you, you should expect to see baseline hormone panels, documented rationale, and a conversation about risks, not a patient success story as the primary evidence. The outcome described may be real for this patient. That does not make it generalizable, and it does not substitute for a proper informed consent discussion.